Immunotherapy for thoracic malignancies
ConclusionWe have highlighted the successes, as well as the limitations, of immunotherapy for non-small cell lung cancer and malignant pleural mesothelioma. We have identified early phase clinical trials that assess immunotherapy as first-line, second-line, and maintenance therapy, and compared these drugs as monotherapeutics or in combination with chemotherapy or other types of immunotherapy.
Source: Indian Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Heart | Immunotherapy | India Health | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Vaccines